ES2742724T3 - Producción de factor X funcional y completamente procesado en un sistema de expresión de mamífero que secreta furina - Google Patents

Producción de factor X funcional y completamente procesado en un sistema de expresión de mamífero que secreta furina Download PDF

Info

Publication number
ES2742724T3
ES2742724T3 ES15757369T ES15757369T ES2742724T3 ES 2742724 T3 ES2742724 T3 ES 2742724T3 ES 15757369 T ES15757369 T ES 15757369T ES 15757369 T ES15757369 T ES 15757369T ES 2742724 T3 ES2742724 T3 ES 2742724T3
Authority
ES
Spain
Prior art keywords
furin
approximately
expression vector
expression
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15757369T
Other languages
English (en)
Spanish (es)
Inventor
Ernst Böhm
Franziska Horling
Jadranka Koehn
Michael Dockal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxalta GmbH
Baxalta Inc
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Application granted granted Critical
Publication of ES2742724T3 publication Critical patent/ES2742724T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21075—Furin (3.4.21.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15757369T 2014-08-12 2015-08-12 Producción de factor X funcional y completamente procesado en un sistema de expresión de mamífero que secreta furina Active ES2742724T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462036438P 2014-08-12 2014-08-12
PCT/US2015/044883 WO2016025615A1 (en) 2014-08-12 2015-08-12 Production of fully processed and functional factor x in a furin-secreting mammalian expression system

Publications (1)

Publication Number Publication Date
ES2742724T3 true ES2742724T3 (es) 2020-02-17

Family

ID=54035298

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15757369T Active ES2742724T3 (es) 2014-08-12 2015-08-12 Producción de factor X funcional y completamente procesado en un sistema de expresión de mamífero que secreta furina

Country Status (14)

Country Link
US (1) US9873892B2 (enExample)
EP (1) EP3180427B1 (enExample)
JP (1) JP6793114B2 (enExample)
CN (1) CN107002041B (enExample)
AR (1) AR102048A1 (enExample)
AU (1) AU2015301726B2 (enExample)
CA (1) CA2958056C (enExample)
EA (1) EA035444B1 (enExample)
ES (1) ES2742724T3 (enExample)
IL (1) IL250530B (enExample)
MX (1) MX377236B (enExample)
NZ (1) NZ729729A (enExample)
TW (1) TWI666319B (enExample)
WO (1) WO2016025615A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
SG11201912962RA (en) 2017-06-23 2020-01-30 Baxalta Inc Purification of factor viii subspecies
WO2020257942A1 (en) * 2019-06-28 2020-12-30 Peel Sean A F A method for increasing yields and the specific activity of certain recombinant proteins in mammalian cells by co-expressing full-length furin
GB202018320D0 (en) * 2020-11-20 2021-01-06 Univ Newcastle Methods of producing recombinant complement proteins
CN115298204B (zh) * 2022-01-25 2023-04-25 青岛万明赛伯药业有限公司 proNGF突变体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4236698B2 (ja) 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
AT404838B (de) * 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
JPH09295945A (ja) * 1996-04-30 1997-11-18 Hoechst Yakuhin Kogyo Kk 成熟型骨誘導因子の製造方法
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
EP1233986A4 (en) 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
EP1622928A4 (en) * 2003-05-09 2006-06-14 Res Dev Foundation INSERTION OF FURINE PROTEASE CLEAVAGE SITES IN MEMBRANE PROTEINS AND USES THEREOF
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
JP5053435B2 (ja) * 2007-05-18 2012-10-17 バクスター・インターナショナル・インコーポレイテッド Ｖｗｆプロペプチドから成熟ｖｗｆを産生するための方法。
CA2710260C (en) * 2007-12-31 2023-07-11 Barbara Plaimauer Substantially animal protein-free recombinant furin and methods for producing same
KR101544245B1 (ko) 2009-02-03 2015-08-12 아뮤닉스 오퍼레이팅 인코포레이티드 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
RU2610436C2 (ru) * 2011-06-02 2017-02-10 Баксалта Инкорпорейтед Составы рекомбинантного фурина

Also Published As

Publication number Publication date
CN107002041B (zh) 2021-06-29
CA2958056C (en) 2023-07-04
IL250530B (en) 2020-03-31
IL250530A0 (en) 2017-03-30
AU2015301726B2 (en) 2021-10-21
WO2016025615A1 (en) 2016-02-18
AU2015301726A1 (en) 2017-03-16
EP3180427A1 (en) 2017-06-21
US20160046957A1 (en) 2016-02-18
TWI666319B (zh) 2019-07-21
AR102048A1 (es) 2017-02-01
US9873892B2 (en) 2018-01-23
JP2017524366A (ja) 2017-08-31
CA2958056A1 (en) 2016-02-18
MX2017001931A (es) 2017-06-30
JP6793114B2 (ja) 2020-12-09
EA201790360A1 (ru) 2017-06-30
EA035444B1 (ru) 2020-06-17
TW201625791A (zh) 2016-07-16
MX377236B (es) 2025-03-07
NZ729729A (en) 2023-07-28
EP3180427B1 (en) 2019-05-22
CN107002041A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
ES2742724T3 (es) Producción de factor X funcional y completamente procesado en un sistema de expresión de mamífero que secreta furina
ES2339953T5 (es) Glicoformas de factor VII ligadas a O y método de fabricación
ES2799735T3 (es) Células de mamífero que expresan antígenos de citomegalovirus
ES2761692T3 (es) Método de producción de vWF recombinante de alto peso molecular en cultivo celular
ES2315022T3 (es) Metodo para la produccion de fvii.
ES2585246T3 (es) Fibrinógeno recombinante
US20040110675A1 (en) Mutant human factor ix with an increased resistance to inhibition by heparin
ES2503365T3 (es) Método para producir proteínas dependientes de vitamina K biológicamente activas por métodos recombinantes
ES2894343T3 (es) Constructos de ácido nucleico para producir vectores retrovirales
CN113396223A (zh) 表达因子ix的慢病毒载体的用途
JP6177130B2 (ja) 第ｉｘ因子活性を有する融合タンパク質
ES2397530T3 (es) Coexpresión recombinante de la subunidad 1 de la epóxido reductasa de la vitamina K para mejorar la expresión de proteína dependiente de la vitamina K
CN110831613A (zh) 因子ix融合蛋白及其制备和使用方法
AR043017A1 (es) Vector de alta expresion para celulas animales
ES2597966T3 (es) Método para la producción en masa de factor VII/VIIa
WO2011092242A1 (en) Factor vii fusion polypeptides
Yang et al. High level expression, purification and activation of human dipeptidyl peptidase I from mammalian cells
Pavirani et al. Structural and functional properties of recombinant coagulation factors